ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for farmasi
  • Artikler, rapporter og annet (farmasi)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for farmasi
  • Artikler, rapporter og annet (farmasi)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

In vitro skin models as a tool in optimization of drug formulation

Permanent link
https://hdl.handle.net/10037/8511
DOI
https://doi.org/10.1016/j.ejps.2015.02.018
Thumbnail
View/Open
article.pdf (653.5Kb)
Accepted manuscript version (PDF)
Date
2015-07-30
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Flaten, Gøril Eide; Palac, Zora; Engesland, André; Filipović-Grčić, Jelena; Vanić, Željka; Skalko-Basnet, Natasa
Abstract
(Trans)dermal drug therapy is gaining increasing importance in the modern drug development. To fully utilize the potential of this route, it is important to optimize the delivery of active ingredient/drug into/through the skin. The optimal carrier/vehicle can enhance the desired outcome of the therapy therefore the optimization of skin formulations is often included in the early stages of the product development. A rational approach in designing and optimizing skin formulations requires well-defined skin models, able to identify and evaluate the intrinsic properties of the formulation. Most of the current optimization relies on the use of suitable ex vivo animal/human models. However, increasing restrictions in use and handling of animals and human skin stimulated the search for suitable artificial skin models. This review attempts to provide an unbiased overview of the most commonly used models, with emphasis on their limitations and advantages. The choice of the most applicable in vitro model for the particular purpose should be based on the interplay between the availability, easiness of the use, cost and the respective limitations
Description
This is accepted manuscript version. Published version available at http://dx.doi.org/10.1016/j.ejps.2015.02.018
Publisher
Elsevier
Citation
European Journal of Pharmaceutical Sciences 2015, 75:10-24
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (farmasi) [394]

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)